Dyax is a fully integrated biopharmaceutical company engaged in discovering, developing and commercializing novel biotherapeutics for unmet medical needs. The KALBITOR (ecallantide) business, the angioedema portfolio and the Licensing and Funded Research Program (LFRP) are the company’s key value drivers. KALBITOR was developed independently by Dyax, and the company has been selling this product in the U.S. since 2010 as a treatment for acute attack of hereditary angioedema in patients 16 and older. For more information, visit the company’s Web site: http://www.dyax.com

Let us hear your thoughts below: